Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma.

Cancer research and treatment - 1 Jul 2022

Hwang Inwoo, Choi Yoon-La, Lee Hyunwoo, Hwang Soohyun, Lee Boram, Yang Hobin, Chelakkot Chaithanya, Han Joungho

Abstract excerpt

PURPOSE: The incidence of BRAF V600E mutation in non-small cell lung carcinoma (NSCLC) is lower than 2%, which poses difficulties in finding legitimate patients for targeted therapy. We investigated the predictive factors pertaining to BRAF V600E and the effectiveness of the VE1 antibody as a screening method for patient selection. MATERIALS AND METHODS: The study was designed into two steps. In a first group,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 34844291
DOI: 10.4143/crt.2021.843
PMCID: PMC9296927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma.PMID 34844291Read ↗

Immunohistochemical Study Using Monoclonal VE1 Antibody Can Substitute the Molecular Tests for Apprehension of BRAF V600E Mutation in Patients with Non-small-Cell Lung Carcinoma.Semantic proximity Read ↗

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.Semantic proximity Read ↗

Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens.Semantic proximity Read ↗

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.Semantic proximity Read ↗

Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).Semantic proximity Read ↗

VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.Semantic proximity Read ↗

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.Semantic proximity Read ↗

A BRAF new world.Semantic proximity Read ↗

BRAF-mutations in non-small cell lung cancer.Semantic proximity Read ↗

BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients.Semantic proximity Read ↗

BRAF V600E mutation-specific antibody: A review.Semantic proximity Read ↗

A literature review of a meta-analysis of BRAF mutations in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.